Researchers found that increased age, female sex, steroids at initial visit and stromal involvement were each linked with higher odds of developing further problems.
At baseline, patients who experienced good outcomes on ranibizumab therapy tended to have higher vascular densities in the superficial and deep capillary plexuses and smaller FAZ areas.
Absence of PVD, Black race, Hispanic ethnicity, diabetic retinopathy and CRVO vs. BRVO incidents are all linked to a higher likelihood. The findings emphasize the importance of early detection and monitoring.
Understanding associations between this medication use and the thinning of retinal regions could serve as an early diagnostic indicator for retinal toxicity.